Healthcare Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), Galena Biopharma (NASDAQ:GALE)

FB Nasdaq FB Facebook

Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) reported financial results for the fourth quarter and year ended December 31, 2013. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) stock performance was -2.29% in last session and finished the day at $3.42. Traded volume was 7.95 million shares in the last session and the average volume of the stock remained 8.89 million shares. The beta of the stock remained 3.55. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) insider ownership is 0.30%.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) and Bristol-Myers Squibb Company (NYSE:BMY) announced yesterday that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform. Bristol-Myers Squibb Co (NYSE:BMY) rose 1.33% to $54.72 yesterday on volume of 7.31 million shares. The intra-day range of the stock was $54.18 – $54.90. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of 90.29 billion.

Johnson & Johnson (NYSE:JNJ) lawsuit sheds light on link between doctors and device makers. Johnson & Johnson (NYSE:JNJ)’s stock on March 17, 2014 reported a higher of 1.21% to the closing price of $93.93. Its fifty two weeks range is $78.50 – $95.99. The total market capitalization recorded 264.88 billion. The overall volume in the last trading session was 5.88 million shares. In its share capital, Johnson & Johnson (NYSE:JNJ) has 2.82 billion outstanding shares.

Galena Biopharma, Inc. (NASDAQ:GALE) the embattled Portland biotechnology company, posted a net loss for the fourth quarter of $48.5 million, or 46 cents a share. On Monday, shares of Galena Biopharma Inc. (NASDAQ:GALE) advanced 2.55% to close the day at $3.22. Company return on investment (ROI) is – and its monthly performance is recorded as -26.15%. Galena Biopharma Inc. (NASDAQ:GALE) quarterly revenue growth is -23.15%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone